The MLA FL Program in 1960

PMLA ◽  
1961 ◽  
Vol 76 (2) ◽  
pp. 15-19
Author(s):  
Donald D. Walsh

You have heard three excellent talks on this, the final session of a three-day meeting that will doubtless seem, to some of you, to have begun three weeks ago. Your arches are fallen, your ears are tired, your lungs are filled with convention hotel air, carefully preserved from one annual meeting to the next, wafted from New York to Chicago to Philadelphia. You have reached the point where, in the memorable words of William Riley Parker, the seats are making more impression on the audience than the speeches. You are ready for a foreign-language funny story, and I happen to have one, which I read in the October number of the Newsletter of the Montana FLTA. Mrs. Smith is complaining to Mr. Jones, the principal of her son's school: “Mr. Jones, my Johnny is an intelligent, conscientious boy. He studies hard and he gets good grades in all his subjects, except one, French. He tries and tries, Mr. Jones, but my Johnny simply can not learn that language!” Mr. Jones: “How fortunate, Mrs. Smith, that your Johnny was not born in France!”

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Jing-Zhou Hou ◽  
Jing Christine Ye ◽  
Jeffrey J. Pu ◽  
Hongtao Liu ◽  
Wei Ding ◽  
...  

AbstractAntibodies and chimeric antigen receptor-engineered T cells (CAR-T) are increasingly used for cancer immunotherapy. Small molecule inhibitors targeting cellular oncoproteins and enzymes such as BCR-ABL, JAK2, Bruton tyrosine kinase, FLT3, BCL-2, IDH1, IDH2, are biomarker-driven chemotherapy-free agents approved for several major hematological malignancies. LOXO-305, asciminib, “off-the-shelf” universal CAR-T cells and BCMA-directed immunotherapeutics as well as data from clinical trials on many novel agents and regimens were updated at the 2020 American Society of Hematology (ASH) Annual Meeting. Major developments and updates for the therapy of hematological malignancies were delineated at the recent Winter Symposium and New York Oncology Forum from the Chinese American Hematologist and Oncologist Network (CAHON.org). This study summarized the latest updates on novel agents and regimens for hematological malignancies from the 2020 ASH annual meeting.


Sign in / Sign up

Export Citation Format

Share Document